within Pharmacolibrary.Drugs.ATC.L;

model L04AB05
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.8,
    Cl             = 0.00016666666666666666,
    adminDuration  = 600,
    adminMass      = 0.4,
    adminCount     = 1,
    Vd             = 0.008,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Certolizumab pegol is a PEGylated, humanized, antigen-binding fragment (Fab’) of a monoclonal antibody directed against tumor necrosis factor alpha (TNF-α). It is used for the treatment of moderate to severe rheumatoid arthritis, Crohn's disease, psoriatic arthritis, and ankylosing spondylitis. It is approved for use in many countries including the US and the EU.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in adult patients with rheumatoid arthritis, following subcutaneous administration.</p><h4>References</h4><ol><li><p>Lee, A, &amp; Scott, LJ (2020). Certolizumab Pegol: A Review in Moderate to Severe Plaque Psoriasis. <i>BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy</i> 34(2) 235–244. DOI:<a href=&quot;https://doi.org/10.1007/s40259-020-00416-z&quot;>10.1007/s40259-020-00416-z</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32207094/&quot;>https://pubmed.ncbi.nlm.nih.gov/32207094</a></p></li><li><p>Blick, SK, &amp; Curran, MP (2007). Certolizumab pegol: in Crohn&#x27;s disease. <i>BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy</i> 21(3) 195–203. DOI:<a href=&quot;https://doi.org/10.2165/00063030-200721030-00006&quot;>10.2165/00063030-200721030-00006</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/17516714/&quot;>https://pubmed.ncbi.nlm.nih.gov/17516714</a></p></li><li><p>Pasut, G (2014). Pegylation of biological molecules and potential benefits: pharmacological properties of certolizumab pegol. <i>BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy</i> 28 Suppl 1 S15–S23. DOI:<a href=&quot;https://doi.org/10.1007/s40259-013-0064-z&quot;>10.1007/s40259-013-0064-z</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/24687235/&quot;>https://pubmed.ncbi.nlm.nih.gov/24687235</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L04AB05;
